Galectin Therapeutics' (GALT) Management Discusses Phase 2b NASH-CX Trial Results Conference Call (Transcript) [Seeking Alpha]
Galectin Therapeutics Inc. (GALT)
Last galectin therapeutics inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.galectintherapeutics.com/investor-relations
Company Research
Source: Seeking Alpha
Galectin Therapeutics, Inc. (NASDAQ: GALT ) Galectin Therapeutics Phase 2b NASH-CX Trial Results Presentation December 05, 2017 08:30 AM ET Executives Peter Traber - Chief Executive Officer and Chief Medical Officer Stephen Harrison - Lead Investigator, NASH-CX Trial Analysts Ed Arce - HC Wainwright and Company Yasmeen Rahimi - ROTH Capital Partners Vernon Bernardino - Seaport Global Len Yaffe - Stockdoc Partners Operator Good day, ladies and gentlemen. And welcome to the Galectin Therapeutics Conference Call and Webcast. All participants will be in listen-only mode [Operator Instructions]. After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Dr. Peter Traber. Please go ahead. Peter Traber Good morning, everyone. My name is Dr. Peter Traber, CEO and CMO of Galectin Therapeutics. We are very pleased to host this
Show less
Read more
Impact Snapshot
Event Time:
GALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GALT alerts
High impacting Galectin Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GALT
News
- Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis Acquire Media Monitor
- Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitisGlobeNewswire
- Galectin Therapeutics Inc. (NASDAQ: GALT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Galectin Therapeutics Inc. (NASDAQ: GALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
GALT
Earnings
- 11/13/23 - Miss
GALT
Sec Filings
- 4/25/24 - Form 4
- 4/25/24 - Form 5
- 4/25/24 - Form 4
- GALT's page on the SEC website